EDEN PRAIRIE, Minn.–()–Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018. Following LaFrence’s departure, Timothy J. Arens, Vice President of Corporate Development and Strategy, will serve as interim CFO.
Name: Andrew LaFrence
Continent: North America
Company: Surmodics, Inc.
Announcement Date: May 15, 2018, 10:00pm
Resignation Date: May 15, 2018, 10:00pm